Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To assess the safety, tolerability and pharmacokinetic characteristics of LC-28-0126 multiple iv injection in healthy male subjects.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| LC28-0126 | Experimental | LC28-0126(IV) |
|
| Placebo | Placebo Comparator | Placebo of LC28-0126 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LC28-0126 | Drug | LC28-0126 |
| |
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse events | 18 days |
| Measure | Description | Time Frame |
|---|---|---|
| Cmax | up to 6 days post-dose | |
| AUC | up to 6 days post-dose |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seoul National University Hospital, Clinical Trial Center | Seoul | 110-744 | South Korea |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32980184 | Derived | Kim E, Hwang I, Lee S, Oh J, Chung H, Jin M, Kim SH, Yu KS. Pharmacokinetics and Tolerability of LC28-0126, a Novel Necrosis Inhibitor, After Multiple Ascending Doses: A Phase I Randomized, Double-blind, Placebo-controlled Study in Healthy Male Subjects. Clin Ther. 2020 Oct;42(10):1946-1954.e2. doi: 10.1016/j.clinthera.2020.08.011. Epub 2020 Sep 24. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Double-blind
| Drug |
Placebo |
|